Merck (NYSE:MRK)
has resubmitted a supplemental marketing to the FDA seeking approval of
a six-week dosing regimen (400 mg infused over 30 minutes) for Keytruda
(pembrolizumab).
The company received a Complete Response Letter (CRL) in February regarding its initial filing.
Currently, the PD-1 inhibitor is administered at 200 mg infused over 30 minutes every three weeks.
https://seekingalpha.com/news/3563509-merck-refiles-u-s-application-for-six-week-dosing-for-keytruda
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.